Yahoo
    NYSE - Delayed Quote USD

    Teva Pharmaceutical Industries Limited (TEVA)

    36.36 -0.26 (-0.71%)
    At close: September 4 at 4:00:02 PM EDT
    37.19 +0.83 (+2.28%)
    After hours: September 4 at 7:59:01 PM EDT
    Trade TEVA on Coinbase
    Loading Chart for TEVA
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

    Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?
    Insider Monkey 18h ago
    S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

    S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
    GlobeNewswire 18h ago
    Outperforming Pharma Stock Still Has Upside Potential

    Outperforming Pharma Stock Still Has Upside Potential
    Schaeffer's Investment Research 1d ago
    TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study

    TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
    Zacks 1d ago
    Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

    Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
    Benzinga 2d ago
    Teva’s mAb shows benefit in celiac disease study

    Teva’s mAb shows benefit in celiac disease study
    Clinical Trials Arena 2d ago
    Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study

    Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study
    Benzinga 2d ago
    Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

    Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
    GlobeNewswire 2d ago
    Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

    Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
    BioPharma Dive 2d ago
    Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study

    Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study
    MarketBeat 2d ago
    J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?

    J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
    Zacks 2d ago

    Related Tickers

    VTRS
    AQST
    RGC
    HIMS
    TLRY
    TAK
    ZTS
    BHC
    CGC
    SXTC
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: